NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $111.01 +1.62 (+1.48%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$111.70 +0.69 (+0.62%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeneDx alerts:Sign Up Key Stats Today's Range$107.96▼$112.0050-Day Range$80.02▼$111.3152-Week Range$10.70▼$115.60Volume619,079 shsAverage Volume697,134 shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$72.33Consensus RatingModerate Buy Company OverviewGeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More… GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 40% of companies evaluated by MarketBeat, and ranked 719th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 1 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth115.46% Earnings GrowthEarnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -56.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -56.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 12.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.28% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.28% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. News and Social Media3.6 / 5News Sentiment1.44 News SentimentGeneDx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for GeneDx this week, compared to 7 articles on an average week.Search Interest14 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,907,437.00 in company stock.Percentage Held by Insiders27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address WGS Stock News HeadlinesInsider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 15,516 Shares of StockApril 11, 2025 | insidertrades.comGeneDx Holdings Corp. (WGS): Among the Best Multibagger Stocks to Buy According to BillionairesApril 24 at 12:48 AM | msn.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.April 26, 2025 | Brownstone Research (Ad)GeneDx Holdings Corp. (WGS) Rose on Robust Customer DemandApril 18, 2025 | finance.yahoo.comCraig-Hallum Sticks to Their Buy Rating for GeneDx Holdings (WGS)April 17, 2025 | markets.businessinsider.comGeneDx to acquire Fabric Genomics for $33M in cash at closingApril 17, 2025 | markets.businessinsider.comGeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global ScaleApril 16, 2025 | businesswire.comGeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025April 8, 2025 | businesswire.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS stock has increased by 44.4% and is now trading at $111.01. View the best growth stocks for 2025 here. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) issued its earnings results on Tuesday, February, 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The company earned $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a positive trailing twelve-month return on equity of 3.33% and a negative net margin of 17.12%. Read the conference call transcript. When did GeneDx's stock split? Shares of GeneDx reverse split before market open on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? GeneDx's top institutional investors include Allspring Global Investments Holdings LLC (0.68%), Assenagon Asset Management S.A. (0.38%), GAMMA Investing LLC (0.14%) and Lisanti Capital Growth LLC (0.10%). Insiders that own company stock include Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Tactical Opportunit Blackstone, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Kevin Feeley, Katherine Stueland, Shawn Assad, Richard Miao and Anthony Prentice. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings2/18/2025Today4/26/2025Next Earnings (Estimated)4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$72.33 High Stock Price Target$118.00 Low Stock Price Target$21.00 Potential Upside/Downside-34.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E Ratio114.44 P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-17.12% Pretax Margin-31.52% Return on Equity3.33% Return on Assets1.69% Debt Debt-to-Equity Ratio0.25 Current Ratio2.40 Quick Ratio2.27 Sales & Book Value Annual Sales$305.45 million Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$8.78 per share Price / Book12.64Miscellaneous Outstanding Shares28,068,000Free Float19,971,000Market Cap$3.12 billion OptionableOptionable Beta1.93 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:WGS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.